The role of delay in stage-III testicular tumors.
Twenty-eight patients with stage-III testicular tumors seen between 1979 and 1984 were analyzed for the effect of delay on diagnosis and chemotherapy and prognosis. A statistically significant relation was determined between the symptom-diagnosis interval and extent of the disease. The complete response (CR) rate was 67% for patients treated within 6 months of symptoms, on the contrary only 16% of patients with interval longer than 6 months to treatment had CR (p less than 0.05). We believe that delay in diagnosis and chemotherapy may affect the response to treatment. Health education of the male population for self-examination of the testes is an important factor for minimizing this delay.
A
A
Akdas
Z
Z
Kirkali
D
D
Remzi
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D004407:Dysgerminoma / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors; D014747:Vinblastine / Q000008:administration & dosage
D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin